Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps

Political momentum and funding for combatting antimicrobial resistance (AMR) continues to build. Numerous major international and national initiatives aimed at financially incentivising the research and development (R&D) of antibiotics have been implemented. However, it remains unclear how to ef...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antibiotics Vol. 70; no. 12; pp. 1087 - 1096
Main Authors: Simpkin, Victoria L, Renwick, Matthew J, Kelly, Ruth, Mossialos, Elias
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 01.12.2017
Nature Publishing Group
Subjects:
692/700
692/700/155
Antibiotics
Bacteriology
Biomedical and Life Sciences
Bioorganic Chemistry
Funding
Life Sciences
Literature reviews
Medicinal Chemistry
Microbiology
Organic Chemistry
Pharmaceutical industry
Public health
R&D
Research & development
Review
review-article
ISSN:0021-8820, 1881-1469, 1881-1469
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Political momentum and funding for combatting antimicrobial resistance (AMR) continues to build. Numerous major international and national initiatives aimed at financially incentivising the research and development (R&D) of antibiotics have been implemented. However, it remains unclear how to effectively strengthen the current set of incentive programmes to further accelerate antibiotic innovation. Based on a literature review and expert input, this study first identifies and assesses the major international, European Union, US and UK antibiotic R&D funding programmes. These programmes are then evaluated across market and public health criteria necessary for comprehensively improving the antibiotic market. The current set of incentive programmes are an important initial step to improving the economic feasibility of antibiotic development. However, there appears to be a lack of global coordination across all initiatives, which risks duplicating efforts, leaving funding gaps in the value chain and overlooking important AMR goals. This study finds that incentive programmes are overly committed to early-stage push funding of basic science and preclinical research, while there is limited late-stage push funding of clinical development. Moreover, there are almost no pull incentives to facilitate transition of antibiotic products from early clinical phases to commercialisation, focus developer concentration on the highest priority antibiotics and attract large pharmaceutical companies to invest in the market. Finally, it seems that antibiotic sustainability and patient access requirements are poorly integrated into the array of incentive mechanisms.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0021-8820
1881-1469
1881-1469
DOI:10.1038/ja.2017.124